ImmunOs Therapeutics AG, a Swiss bio-technology company leading development of a next generation innate and adaptive immunity focused immunotherapy platform for cancer, announced the closing of its 2.3 Million CHF financing round. The proceeds of the financing will be used to advance its lead clinical candidate, a single multitasking protein agent, for treating solid tumors.
VISCHER acted as counsel to ImmunOs. The team was led by Christian Wyss (Partner) and supported by Luzius Zumstein (Associate), both Corporate.